Entera Bio To Present Two Abstracts On Its Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) For The Treatment Of Post-Menopausal Women At High Risk Of Fracture At The American Society For Bone And Mineral Research Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Entera Bio will present two abstracts on its once-daily oral hPTH(1-34) peptide tablets (EB613) for the treatment of post-menopausal women at high risk of fracture at the American Society for Bone and Mineral Research Annual Meeting.
August 16, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entera Bio's presentation of two abstracts on its EB613 tablets at the ASBMR Annual Meeting could potentially boost its reputation in the healthcare sector.
The presentation of two abstracts on its EB613 tablets at a prestigious meeting like the ASBMR Annual Meeting could potentially boost Entera Bio's reputation and credibility in the healthcare sector. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100